Targets › CYP51A1
4 programs from 4 companies in 7 trials: 4 Phase 2, 1 Phase 4, 1 Phase 3, 1 Phase 1; Infectious disease, Oncology, Immunology; next expected readout Mar 2027.
Sterol 14alpha-demethylase that plays a critical role in the cholesterol biosynthesis pathway, being cholesterol the major sterol component in mammalian membranes as well as a precursor for bile acid and steroid hormone synthesis. Cytochrome P450 monooxygenase that catalyzes the three-step oxidative removal of the 14alpha-methyl group (C-32) of sterols such as lanosterol (lanosta-8,24-dien-3beta-ol) and…. (UniProt, Q16850)
Open in Phaseline: the race on CYP51A1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Weill Medical College of Cornell University | Fluconazole Cytochrome P450 51 inhibitor | CYP51A1 | Phase 3 | Crohn's Disease | Dec 2028 |
| Merck & Co. (MSD) | Posaconazole (MK-5592) Cytochrome P450 51 inhibitor | CYP51A1 | Phase 2 | Invasive Fungal Infection; Posaconazole; Breast Cancer; Hematologic Malignancy | Mar 2027 |
| David Boulware | Oteseconazole Azole metalloenzyme inhibitor targeting fungal sterol 14α demethylase (CYP51) | CYP51A1 | Phase 2 | Hiv | Apr 2032 |
| University of California, Davis | Ketoconazole Cytochrome P450 51 inhibitor | CYP51A1 | Phase 1 | Healthy | – |
Invasive Fungal Infection (1) Posaconazole (1) Breast Cancer (1) Hematologic Malignancy (1) Crohn's Disease (1) Healthy (1) Hiv (1)
small molecule (3), mixed (1)
Merck & Co. (MSD) (1) Weill Medical College of Cornell University (1) University of California, Davis (1) David Boulware (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.